Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.
Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.
Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.
Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases.
In a recent study using mice, lab-grown human retinal cells and patient samples, Johns Hopkins Medicine scientists say they found evidence of a new pathway that may contribute to degeneration of the light sensitive tissue at the back of the eye.
A new Taiwanese study presented on October 14, 2019, at the Annual Meeting of the American Academy of Ophthalmology, reports that macular edema in diabetes occurs more often in those who have severe sleep apnea.
New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases.
This HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR).
A change to the approach for treating diabetic macular edema may be on the way, thanks to a study published today in the Journal of the American Medical Association.
In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.
When it comes to understanding how neurons connect to form circuits in the brain, scientists for decades have turned to the retina of the humble laboratory mouse as an ideal model organism. But as a model for vision and vision-related diseases, mice simply aren't equipped.
Researchers have used artificial intelligence to support the instant diagnosis of one of the top causes of blindness, diabetes-related eye disease, in its earliest stages.
RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute to develop a new drug for degenerative eye disorders.
Diabetes is an increasing global epidemic that is expected to grow by more than 50 percent in the next two decades, leaving more than half a billion patients worldwide exposed to potentially life-altering medical complications, including pain and numbness in the feet, lost limbs, life-threatening disorders of the heart, liver and kidneys -- and even blindness.
The American Academy of Ophthalmology today announced key milestones and clinical insights from studies powered by its clinical database.
It is no secret that the issues associated with current glaucoma medications can be problematic. Systemic medications carry the risk of side effects, while the current medical treatment of choice, eye drops, has its own drawbacks.
In photographs of the eye used to screen for diabetes-related eye disease, separating out the red color channel can help show some abnormalities—especially in racial/ethnic minority patients, suggests a study in the February issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
The standard of care for treating strokes caused by blood clots involves the therapeutic infusion of tissue plasminogen activator (tPA), which can help to dissolve the clots and restore blood flow.
ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).